[go: up one dir, main page]

DK3220891T3 - Sublingual formulering af riluzol - Google Patents

Sublingual formulering af riluzol Download PDF

Info

Publication number
DK3220891T3
DK3220891T3 DK15823415T DK15823415T DK3220891T3 DK 3220891 T3 DK3220891 T3 DK 3220891T3 DK 15823415 T DK15823415 T DK 15823415T DK 15823415 T DK15823415 T DK 15823415T DK 3220891 T3 DK3220891 T3 DK 3220891T3
Authority
DK
Denmark
Prior art keywords
riluzol
sublingual formulation
sublingual
formulation
Prior art date
Application number
DK15823415T
Other languages
English (en)
Inventor
Vladimir Coric
Robert M Berman
Ronald Samuel Vladyka
Amgad Saleh
Danny Yu
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Application granted granted Critical
Publication of DK3220891T3 publication Critical patent/DK3220891T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK15823415T 2014-11-21 2015-11-17 Sublingual formulering af riluzol DK3220891T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462083094P 2014-11-21 2014-11-21
PCT/US2015/061114 WO2016081472A1 (en) 2014-11-21 2015-11-17 Sublingual formulation of riluzole

Publications (1)

Publication Number Publication Date
DK3220891T3 true DK3220891T3 (da) 2019-11-04

Family

ID=55085882

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15823415T DK3220891T3 (da) 2014-11-21 2015-11-17 Sublingual formulering af riluzol

Country Status (24)

Country Link
US (3) US11660267B2 (da)
EP (3) EP3616686B8 (da)
JP (3) JP6753860B2 (da)
KR (2) KR102811263B1 (da)
CN (1) CN107249567B (da)
AU (2) AU2015350148B2 (da)
BR (1) BR112017010423B1 (da)
CA (1) CA2967662A1 (da)
CY (1) CY1122469T1 (da)
DK (1) DK3220891T3 (da)
EA (1) EA038518B1 (da)
ES (2) ES2882783T3 (da)
HR (1) HRP20191892T8 (da)
HU (1) HUE046869T2 (da)
IL (2) IL278188B2 (da)
LT (1) LT3220891T (da)
MX (1) MX368838B (da)
PH (1) PH12017500934B1 (da)
PL (1) PL3220891T3 (da)
PT (1) PT3220891T (da)
RS (1) RS59490B1 (da)
SG (1) SG11201703896QA (da)
SI (1) SI3220891T1 (da)
WO (1) WO2016081472A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102173463B1 (ko) 2016-10-11 2020-11-04 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적 분해용 화합물 및 방법
JP7354123B2 (ja) * 2018-02-21 2023-10-02 エイアイ・セラピューティクス・インコーポレーテッド アピリモドとグルタミン酸作動薬を用いた併用療法
US12364687B2 (en) * 2018-05-27 2025-07-22 Biohaven Therapeutics Ltd. Use of riluzole oral disintegrating tablets for treating diseases
JP2021534160A (ja) * 2018-08-16 2021-12-09 バイオヘイブン・セラピューティクス・リミテッドBiohaven Therapeutics Ltd. 疾患処置のためのリルゾール口腔内崩壊錠の使用
IL292359A (en) * 2019-10-22 2022-06-01 Arvinas Operations Inc Prostate cancer treatment methods
TW202208345A (zh) 2020-05-09 2022-03-01 美商亞文納營運公司 雙官能性化合物的製造方法、該雙官能性化合物的超純形式、及含彼之劑型
WO2022076321A1 (en) * 2020-10-05 2022-04-14 Icahn School Of Medicine At Mount Sinai Riluzole for the treatment of alzheimer's disease
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022103635A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN113876735B (zh) * 2021-10-20 2023-05-12 陇南市第一人民医院 一种利鲁唑微球制剂及其制备方法
KR102625977B1 (ko) 2021-11-24 2024-01-17 부산대학교 산학협력단 리루졸을 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물
WO2025122895A1 (en) 2023-12-08 2025-06-12 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
DE69429119T2 (de) 1993-07-09 2002-07-18 R.P. Scherer Corp., Troy Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
JP2001507222A (ja) * 1996-12-20 2001-06-05 ニュートリノウヴァ・ニュートリション・スペシャルティーズ・アンド・フード・イングリーディエンツ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 極めて強力な甘味料の混合物の甘味力を向上させそして味を向上させる方法
CA2281473C (en) 1997-02-20 2007-01-16 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
WO1999004758A1 (en) 1997-07-25 1999-02-04 Elan Corporation Plc A process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets
AU767154B2 (en) 1998-11-20 2003-10-30 Skyepharma Canada Inc. Dispersible phospholipid stabilized microparticles
ATE289800T1 (de) * 1998-12-09 2005-03-15 Chiron Corp Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems
FR2787028B1 (fr) 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
JP2001328947A (ja) * 2000-05-19 2001-11-27 Ritsuko Senba 脳由来神経栄養因子発現促進剤
US6432992B1 (en) * 2000-06-05 2002-08-13 Aventis Pharm Sa Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
CA2463495C (en) 2001-10-12 2011-05-24 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
AU2003211051A1 (en) 2002-02-13 2003-09-04 Michael K. Weibel Drug dose-form and method of manufacture
EP2316469A1 (en) * 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
WO2004105756A2 (en) * 2003-05-29 2004-12-09 Novartis Ag Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
WO2005084377A2 (en) * 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007074472A2 (en) 2005-12-27 2007-07-05 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide
GB0625322D0 (en) * 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
EP1980240A1 (en) * 2007-04-11 2008-10-15 Cephalon France Lyophilized pharmaceutical compositions and methods of making and using same
JP5269894B2 (ja) 2007-06-27 2013-08-21 ハンミ ファーム． シーオー．， エルティーディー． 経口投与用速溶性製剤の製造方法及びその製造、並びに包装装置
WO2010009279A1 (en) * 2008-07-15 2010-01-21 University Of Medicine And Dentistry Of New Jersey Methods and compositions for treating alzheimer's disease
US8518031B2 (en) 2008-10-31 2013-08-27 The Invention Science Fund I, Llc Systems, devices and methods for making or administering frozen particles
US8731842B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
WO2010096869A1 (en) * 2009-02-26 2010-09-02 Steven Michael Weiss An agent for improving inotropy and lusitropy, and for treating diseases causing or caused by poor contractility or relaxation of the heart
EP2228054A1 (en) 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
US9241933B2 (en) * 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
UA113165C2 (xx) * 2011-03-01 2016-12-26 Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
PT2560631E (pt) * 2011-03-01 2014-02-24 Pharnext Terapia à base de baclofeno e acamprosato de distúrbios neurológicos
CN109316480A (zh) 2011-07-13 2019-02-12 赛特凯恩蒂克公司 组合als疗法
CA2864008C (en) 2012-03-01 2020-04-21 Pharnext New compositions for treating amyotrophic lateral sclerosis
US20180153862A1 (en) 2014-11-21 2018-06-07 Biohaven Pharmaceutical Holding Company Limited (B Sublingual administration of riluzole
AU2016226463B2 (en) * 2015-03-03 2020-06-25 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use

Also Published As

Publication number Publication date
EA201790958A1 (ru) 2018-01-31
US20180153794A1 (en) 2018-06-07
IL252285A0 (en) 2017-07-31
AU2015350148B2 (en) 2020-11-26
KR20170137032A (ko) 2017-12-12
RS59490B1 (sr) 2019-12-31
US11660267B2 (en) 2023-05-30
US12121609B2 (en) 2024-10-22
PH12017500934A1 (en) 2017-11-20
US20250114301A1 (en) 2025-04-10
EP4039247A2 (en) 2022-08-10
EP4039247B1 (en) 2025-11-05
CN107249567A (zh) 2017-10-13
AU2021201034B2 (en) 2023-07-06
HUE046869T2 (hu) 2020-04-28
JP2017535613A (ja) 2017-11-30
EP3616686B1 (en) 2021-05-19
US20210038499A1 (en) 2021-02-11
HRP20191892T8 (hr) 2020-09-18
BR112017010423B1 (pt) 2023-09-26
SG11201703896QA (en) 2017-06-29
SI3220891T1 (sl) 2020-02-28
IL278188A (en) 2020-11-30
EA038518B1 (ru) 2021-09-09
PH12017500934B1 (en) 2024-06-28
BR112017010423A2 (pt) 2017-12-26
IL278188B2 (en) 2025-03-01
WO2016081472A1 (en) 2016-05-26
IL278188B1 (en) 2024-11-01
JP2023065398A (ja) 2023-05-12
EP3616686A1 (en) 2020-03-04
KR102580378B1 (ko) 2023-09-19
CY1122469T1 (el) 2021-01-27
KR102811263B1 (ko) 2025-05-23
EP3616686B8 (en) 2021-06-23
ES2882783T3 (es) 2021-12-02
ES2751300T3 (es) 2020-03-31
HRP20191892T1 (hr) 2020-01-10
PL3220891T3 (pl) 2020-08-24
CA2967662A1 (en) 2016-05-26
CN107249567B (zh) 2021-08-03
EP4039247A3 (en) 2022-11-16
AU2021201034A1 (en) 2021-03-11
LT3220891T (lt) 2019-11-11
KR20230135183A (ko) 2023-09-22
AU2015350148A1 (en) 2017-06-15
EP4039247C0 (en) 2025-11-05
JP2021001173A (ja) 2021-01-07
MX368838B (es) 2019-10-18
JP6753860B2 (ja) 2020-09-09
EP3220891A1 (en) 2017-09-27
MX2017006446A (es) 2018-02-12
IL252285B (en) 2020-10-29
EP3220891B1 (en) 2019-07-24
PT3220891T (pt) 2019-10-31

Similar Documents

Publication Publication Date Title
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3371171T3 (da) Inhibitorer af RET
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3851537T5 (da) Behandling af hyperbilirubinæmi
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3180331T3 (da) Polymorfer af selinexor
DK3215173T3 (da) Glycopeptidsammensætninger
DK3220891T3 (da) Sublingual formulering af riluzol
DK3514109T3 (da) Hydropyrolyse af biomasseholdige råmaterialer
DK3132009T3 (da) Fremgangsmåde
DK3283210T3 (da) Fremgangsmåde
IL248223A0 (en) Vaccine compositions
DK3418273T3 (da) Derivater af flavagliner
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3137449T3 (da) Fremgangsmåder til fremstilling af substituerede cycloseriner
CL2017000639A1 (es) Composición
DK3113773T3 (da) Krystallinske former af grapiprant
IL254502B (en) Solid forms of menaquinols
DK2910535T3 (da) Sammensætning til anvendelse af ekspanderet perlit
DK3173071T3 (da) Formularing af maropitant
DK3212800T3 (da) 21-hydroxylering af steroider
DK3200827T3 (da) Sammensætninger
FR3024647B1 (fr) Transat de puericulture